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ABSTRACT OF DISSERTATION

FUNCTIONAL IMPACT OF ANGIOTENSINOGEN SPECIFIC DOMAINS ON
ANGIOTENSIN II-MEDIATED FUNCTIONS
Angiotensinogen (AGT) is the only substrate for all angiotensin peptides in the
renin angiotensin system (RAS). Cleavage of AGT by renin is a rate-limiting step of
angiotensin peptides productions in the RAS and regulates angiotensin peptides-associated
pathophysiological functions. Only ten N-terminal residues are cleaved by renin and the
functions of remaining part of AGT protein, which is called des(angiotensin I)AGT, remain
unclear. Despite of pivotal roles of AGT in the RAS, studies related to how AGT is
metabolized and how des(angiotensin I)AGT regulates AGT functions or AngII-mediated
functions are limited.
Renin cleavage of AGT shows species specificity. It has been reported that residues
in N-terminus of AGT surrounding renin cleavage site play important roles of affecting
renin activity in vitro by using synthetic peptides. However, there is no in vivo evidence
showing the effects of N-terminal residues in renin cleavage of AGT and consequently
AngII-mediated functions, such as blood pressure and atherosclerosis. In this study, we
compared expressions of AGT proteins by adeno-associated viral (AAV) vectors encoding
human AGT or mouse AGT with Leu11Val and Tyr12Ile mutations which mimics two
residues at the same position in human AGT to determine whether substitution of these
residues regulated AngII-mediated functions. All mice were LDL receptor-/- mice.
Hepatocyte-specific AGT deficient (hepAGT-/-) mice were injected with AAVs encoding
null AAV, human AGT AAV or mutated mouse AGT (L11V;Y12I). hepAGT+/+ littermates
injected with null AAV as positive controls. Expression of human AGT did not affect
endogenous mouse AGT expression, blood pressure and atherosclerosis in hepAGT-/- mice.
In a subsequent study, expression of L1V;Y12I AGT significantly increased plasma AGT
concentration, blood pressure and atherosclerosis, showing that replacement of L11 and
Y12 to V11 and I12, respectively, in mouse AGT does not affect renin cleavage, blood
pressure, and atherosclerosis in LDL receptor deficient mice.
AGT has been reported to have both AngII-dependent and -independent functions.
In our previous publication, we found two highly conserved regions, the β-sheet and loop
region, on the surface of AGT which are distal to renin interacting face, and showed that
these two highly conserved regions might have renin-independent roles. Moreover, we
demonstrated that AGT and megalin interactions predispose animals to atherosclerosis.
Thus, in this study, we investigated whether these two highly conserved regions affect
AngII-mediated functions thorough influencing AGT interaction with megalin. Firstly, we
determined the roles of the loop region in the interaction of AGT with megalin in vitro. All
mice were LDL receptor-/- background. However, repopulation of mouse AGT with single
nucleotide mutation on the loop region, triple nucleotide mutations on the β-sheet or the
loop region, and replacement of whole conserved sequences in the loop region with a GA
linker did not change blood pressure and atherosclerosis in hepAGT-/- mice, which is
associated with plasma AGT concentration. Interestingly, mutations on both the β-sheet

and loop region inhibited plasmas AGT level, blood pressure and atherosclerosis, showing
the β-sheet and loop region synergistically regulate AGT production and consequently
affect AngII-mediated functions in hepAGT-/- mice.
Taken together, residues in AGT have different biological effects which regulates
angiotensin-associated functions.
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CHAPTER 1. LITERATURE REVIEW – CRITICAL ROLES OF ANGIOTENSINOGEN IN ANGIIMEDIATED FUNCTIONS
This chapter provides an introduction to relevant concepts of my research works in
this dissertation. This dissertation discusses the possible roles of specific amino acids of
AGT in AGT metabolism and AngII-mediated functions.

1.1

Introduction
The renin angiotensin system (RAS) is a well-known hormone system regulating

body fluid and blood pressure [1, 2]. Angiotensinogen (AGT), the only substrate of the
RAS to produce all angiotensin peptides, is converted into angiotensin I (AngI) by renin.
AngI is then converted to angiotensin II (AngII) by angiotensin-converting enzyme (ACE).
AngII is an octapeptide which mediates angiotensin II receptor type 1 (AT1)-mediated
physiological and pathological functions. (Figure. 1.1). Human AGT is 452 amino acids
long and mouse AGT is 453 amino acids long. Since the pivotal roles of AGT in the RAS,
AGT regulates AngII production and AngII-mediated functions, such as atherosclerosis
and hypertension.

Figure 1.1 Angiotensinogen is the only substrate of the renin angiotensin system.

Atherosclerosis, a disease caused by plaque building-up inside arterial wall, is a
leading risk factor of many cardiovascular diseases [3]. It has been reported by many
groups that the RAS is involved in the pathogenesis of atherosclerosis [4-6]. In the RAS,
AngII is a major factor contributing to vascular pathology by direct and indirectly affecting
vascular wall and various types of cells (Figure 1.2) [6-8]. AngII induces oxidative stress
[9-11], inflammatory cytokines and adhesion molecules production [12, 13], LDL
oxidation and uptake [14, 15], and endothelial dysfunction [16]. For example, AngII
infusion (500 ng/kg/min) for 28 days increased cholesterol accumulation in atherosclerotic
lesions in LDL receptor-/- mice [17]. AngII infusion (1000 ng/kg/min) for 28 days
increased macrophage accumulation in atherosclerotic lesions and promoted severity of
atherosclerosis in apoE-/- mice [6]. Inhibition of AngII production by blocking renin [1820] or ACE [21-24] attenuates atherosclerosis. In addition, AT1 receptor antagonism by
AT1 receptor blocker or genetic knockout attenuates atherosclerosis in animals and human.
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In animals, AT1 receptor antagonists, such as losartan [25-27], valsartan [28, 29] and
irbesartan [30, 31], olmesartan [32] and telmisartan [33], significantly decreased intimal
lesions in hypercholesterolemia-induced atherosclerosis in monkeys, rabbits or mice.
AT1A

receptor

deficiency

significantly

reduces

hypercholesterolemia-induced

atherosclerosis in LDL receptor-/- mice [34, 35], which associates with the decrease in
hypercholesterolemia-enhanced systemic AGT and angiotensin peptides [35]. AT1A
receptor deficiency also attenuates vascular dysfunction and atherosclerosis in apoE-/- mice
[36, 37]. In human, irbesartan attenuates inflammatory markers in premature forms of
atherosclerosis [38] and inhibits MMP-induced plaque rupture by blocking COX2/mPGES-1 expression [39]. Losartan [40, 41] and olmesartan [42] significantly reduce
intima-media thickness in patients with hypertension. Taken together, AngII-AT1 receptor
pathway regulates and promotes the formation of atherosclerosis.

Figure 1.2 Renin angiotensin system contributes to atherosclerosis.

Reports show that the RAS elevates blood pressure in human and animals. In
human, drug interventions to treat hypertension are well established. However,
hypertension-related cardiovascular complications, such as left ventricular hypertrophy
(LVH), are commonly seen in hypertensive patients. Angiotensin II receptor blockers
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(ARBs), which have been widely used for lowering blood pressure in hypertensive
patients, show beneficial effects on hypertension-related cardiovascular complications.
For example, losartan not only reduced blood pressure but also prevented

more

cardiovascular morbidity and death than atenolol, a β-blocker, did [43, 44]. Losartan
reduced blood pressure, protected arterial structure as well as endothelial functions [45],
and regressed myocardial fibrosis [46] in hypertensive patients . To better understand the
roles of the RAS components in the regulation of blood pressure, inhibition of the RAS
components was studied in animal models. For example, losartan, an AT1 receptor
antagonist, blunted the blood pressure increase caused by diet-induced obesity in male
Sprague-Dawley rats [47]. When administered either acutely or chronically, enalapril, an
angiotensin converting enzyme inhibitor, decreased blood pressure in rats [48].
Angiotensin type 1a (AT1a) receptor-/- mice showed significantly decreased blood
pressure [49].
AGT is the only precursor of AngII. There is also evidence that AGT is associated
with AngII-dependent vascular pathology and blood pressure regulation. In
atherosclerosis, single nucleotide polymorphisms of AGT are associated with coronary
atherosclerosis. For example, T704C [50], T174M [51, 52] and M235T [51, 53-55] of
AGT are associated with coronary atherosclerosis in different populations. In addition,
deficiency of plasma AGT significantly decreased atherosclerotic lesions in hepatocytespecific AGT deficient mice [56-59]. hypoAGT mice, which had greatly reduced AGT
mRNA abundance in all tissues, also showed significant decrease in atherosclerosis and
blood pressure [59]. Antisense oligonucleotides targeting AGT attenuated high blood
pressure, atherosclerosis and many other diseases [60-62]. In hypertension, overexpression
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of rat AGT increased plasma AGT concentration and blood pressure in mice [63]. Whole
body AGT knockout mice, which had severe impact on neonatal survival rate and renal
functions, showed hypotension [64]. Infection of adeno-associated viral vector encoding
AGT antisense oligonucleotide in spontaneously hypertensive rats significantly decreased
blood pressure with a short-term [65, 66] or a long-term effect [67]. Small interfering
RNAs (siRNAs) targeting hepatic AGT reduced blood pressure [68, 69], and inhibited
preeclamptic phenotypes [70]. In summary, these findings reveal the important roles of
AGT in AngII-mediated functions.

1.2
1.2.1

Molecular characteristics of AGT
AGT gene and protein structure
AGT is present throughout vertebrate evolution and is conserved from lampreys to

human [71]. Human AGT, which is localized on chromosome 1 and consists of 5 exons
[72, 73], is 485 amino acids with a 33-amino acids signal peptide [74]. Mouse AGT, which
is located on chromosome 8 and consists of 6 exons [75, 76], is 477 amino acids including
a 24-amino acids signal peptide. AngI, 10 N-terminal amino acids, is cleaved from AGT
and the remaining part of AGT which is called as des(AngI)AGT.

1.2.2

Effects of conserved and non-conserved residues of AGT on AGT metabolism
Amino acids determine gene expression and protein functions. There are many

studies reporting amino acids of AGT, such as genetic variants and formation of disulfide
bond, affect AGT expression and production as well as AGT-associated diseases.
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1.2.2.1 Genetic variants
Genetic variants have been showed to regulate AGT expression and associate with
hypertension and other diseases. Two variants of the AGT gene, M235T and T174M, have
been extensively studied and shown to be associated with hypertension [77-82] and other
cardiovascular diseases [83-85] in certain populations, such as Japanese and Caucasians.
For example, M235T of AGT predisposed to hypertension and associated with
cardiovascular risk factors in Japanese [80], and also associated with pre-eclampsia [86].
M235T of AGT was independently and significantly associated with coronary heart
diseases in Caucasians [83]. A meta-analysis which included 127 studies published
between January 1992 and March 2002 showed the association of M235T of AGT with
plasma AGT concentration and risk of hypertension [87]. T174M of AGT was significantly
associated with systolic blood pressure only in men in the Hutterite Brethren, a North
American religious genetic isolate [88]. In addition, other gene polymorphisms of AGT,
such as T704C are associated with cardiovascular diseases, including coronary
atherosclerosis [50]. However, some studies showed that M235T or T174M of AGT might
not be a risk factor for hypertension or coronary heart disease in some ethnic populations,
such as Indian [89], East Anglian subjects of the United Kingdom[90], Chinese [91],
African Caribbean [92], and African American [93].
Genetic variants have been found to contribute to AGT production, which might be
the reason causing hypertension and cardiovascular diseases. It was reported that higher
frequency of T235 of AGT in black children had higher plasma AGT concentration than
in white children [94]. Also, higher plasma AGT concentration was found in female
15

carrying M235T than in male in Lake Salt City [95]. To understand the causality between
AGT gene with plasma AGT concentration and hypertension, genetic mice with zero- to
four- copy of mouse AGT gene in normal chromosomal location were generated and tested.
Plasma AGT concentration was gradually increased in a copy number-dependent manner,
which positively related to blood pressure [96].
These studies show that genetic variants of AGT, such as M235T and T174M
determine AGT production and downstream AngII-regulated blood pressure as well as
cardiovascular diseases based on gene frequency, gender, ages, and ethnics.

1.2.2.2 Disulfide bond
There are four cystines in AGT and two cystines (Cys18-Cys138 in human and
Cys18-Cys137 in mouse) forming a disulfide bond are conserved among species [97, 98].
Cys18-Cys138 disulfide bond has been reported to involve in regulation of structure of Nterminus of AGT [97]. Zhou et al. (2010) reported that Cys18-Cys138 disulfide bond
facilitated active site cleft of renin binding on N-terminus of AGT and consequently
enhanced cleavage of AGT to release AngI by protein crystal structure analysis [99].
Moreover, they found that percentage of reduced form of AGT decreased which means
oxidized AGT increased in pregnant women with preeclampsia, showing redox-switch of
AGT regulates AngII production and hypertension. Rahgozar et al. [100] used another
method, ELISA to measure plasma total and reduced AGT and confirm Zhou et al. results
done by Western blot analysis. Rahgozar et al. in 2015 showed the same result that reduced
AGT significantly decreased in pregnant women with preeclampsia. Most recently,
Dahabiyeh et al. (2020) confirmed decreased ratio of oxidized AGT to total AGT in
16

pregnant women with preeclampsia by a mass spectrometry-based method [101]. However,
repopulation of mutated AGT with lacking Cys18-Cys137 disulfide bond in hepatocytespecific AGT deficient mice did not affect blood pressure and atherosclerosis, showing
that Cys18-Cys137 disulfide bond formation is not essential for AgnII production and
AngII-mediated functions in mice [56]. In summary, disulfide bond formation might
determine AGT metabolism and predisposes to hypertension in human, but not mice.

1.2.2.3 Residues surrounding renin cleavage site

AngI (amino acid position at 1- 10 of AGT) is highly conserved between species;
however, amino acid residues adjacent to AngI is not conserved in species (Fig. 1.3).
Therefore, N-terminal amino sequences of AGT has been assumed as the factor regulating
the interaction of AGT to renin and catalytic activity of renin cleavage of AGT. It was
reported that removal of tyrosine at C-terminal position 2 of renin cleavage site abolished
synthetic substrate activity to hog renin [102]. Tewksbury et al. showed the potential effect
of residue at position 3 at C-terminal side of renin cleavage site on Kcat/Km of renin [103].
Cumin et al. showed that N-terminal residues at position 11 to 14 play an important role
of renin cleavage efficiency, especially 12’ Ile replaced by Tyr in human tetradecapeptide
[104]. Replacement of residues at position 1 and 2 adjacent to renin cleavage site of human
AGT to mimic the two residues at the same position of canine AGT significantly enhanced
Kcat/Km of canine renin [105]. Moreover, amino acids at position 12 and 13 of human Nterminus of AGT are seemed to affect the catalytic reaction of renin [106]. Although these
show the important roles of amino acid residues adjacent to renin cleavage site in catalytic
efficiency of renin and AngI production, these studies used synthetic peptides and in vitro
17

assays. Therefore, in vivo evidence, such as mouse study, is needed to investigate functions
of amino acids around renin cleavage site in AGT metabolism.

Figure 1.3 Amino acid sequence of N-terminus part of natural renin substrates.

1.2.2.4 Conserved residues in des(AngI)AGT structure
AGT is cleaved by renin to release 10 amino acids-long AngI and des(AngI)AGT
which is the remaining part of AGT (98% of AGT). AngI is cleaved by ACE to produce
AngII, which affects and regulates many physiological and pathophysiological functions.
However, studies of functions of remaining part of protein, des(AngI)AGT is limited. It
has been reported that des(AngI)AGT inhibited angiogenesis [107, 108]. Lu et al. reported
that repopulation of des(AngI)AGT in hepatocyte-specific AGT deficient mice increased
body weight and liver steatosis, but did not affect atherosclerosis, showing that
des(AngI)AGT exerted an AngII-independent functions [59]. Interestingly, Lu et al.
aligned the amino acid sequences of AGT from human, rat, mouse and zebrafish, and
mapped the sequences onto the published structure of AGT [99], and found two highly
conserved regions, the β-sheet and loop region, on the surface of AGT which are distal to
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renin-interacting face (Fig. 1.4). These regions may display renin or AngII-independent
functions.

Figure 1.4 Structural analysis of highly conserved regions in des(AngI)AGT

1.3

Regulation of AGT expression
AGT production is regulated by many molecules, such as steroid hormones,

cytokines and AngII [109]. These molecules regulate the activation of transcription factors
which stimulate AGT transcription and consequently enhance AGT synthesis. There are
many other factors affecting AGT expression as well, such as nutritional conditions [110],
sodium concentration [111-113], hypoxia [114], fatty acids [115], insulin [116] and
hyperglycemia [117].
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Glucocorticoid (GC) administration increased AGT expression and production
[118-121]. Two glucocorticoid response elements (GREs) in 5’-flanking region of AGT
gene are essential for GC induction [122, 123]. Estrogen is one of steroid hormones
inducing AGT expression. Estrogen administration increased AGT mRNA level in a
tissue-specific manner in ovariectomized rats [124]. It has been found that a halfpalindromic estrogen-response element is located on 5’-flanking region of rat AGT gene
[123], showing a mechanism how estrogen activates AGT transcription.
In addition, AGT transcription can be induced by cytokines, such as interleukin-lα
(IL-lα) and tumor necrosis factor (TNF), which is mediated by an acute phase response
element (APRE) [125-127]. Ron et al. indicated that glucocorticoid is necessary for IL-lαinduced AGT expression [128]. Lipopolysaccharide (LPS), a bacterial endotoxin
stimulating host immune defense, induces AGT production [129], which is mediated by
TNF-a and IL-6 pathways [130, 131], showing important effects of inflammation on AGT
gene activation.
Positive feedback regulation of AGT synthesis mediated by AngII, its end product,
is one of important regulations of AGT production [132]. For examples, 3 days of AngII
infusion significantly increased plasma AGT concentration in male Sprague-Dawley rats
with elevated plasma and renal AGT mRNA abundance [133].

1.4

Tissue and cellular distribution of AGT
AGT is expressed in many tissues, such as liver, kidney, brain, adipose tissue, aorta

and heart [119]. Local AGT expression may regulate local tissue functions. AGT is mainly
produced in hepatocytes in liver [134]. Liver-derived AGT is released to circulation [56,
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57, 59, 134, 135] and transported to kidney by a megalin-dependent mechanism [135].
Deficiency of hepatocyte-derived AGT significantly decreased plasma and renal AGT
concentration, showing liver is the primary source of AGT production. Moreover, AGT
has been reported to express in kidney [136] and primarily in S3 segment of renal proximal
tubules [137-139]. Diet-feeding with different salt levels [112] or plasma glucose
concentrations [140, 141] regulates renal AGT expression. Adipose tissues have been
reported as one of sources of plasma AGT [142-144]. AGT expression in adipose tissues
[145-147] is associated with development of obesity [148, 149] and affects blood pressure
[143, 144]. AGT mRNA is also found in whole aorta as well, predominantly in adventitia
[150, 151]. Tissue-specific AGT expression is associated with regulation of local or
systemic RAS.

1.5

Conclusions and perspectives
Evidence showing the critical roles of AGT in regulation of the RAS and RAS-

related diseases in a tissue-dependent and dose-dependent manners. Although it is known
that AGT determines the production of angiotensin peptides which affect physiological
and pathological functions, the studies investigating the functions of whole and cleaved
AGT in AGT metabolism and consequently angiotensin peptide-associated functions are
limited. There are still many unknown questions: (1) There are several in vitro studies
showing the potential effects of amino acids surrounding renin cleavage site on influencing
renin cleavage of AGT. However, there is no in vivo study to prove the effects of these
amino acids of AGT on renin activity. Do these amino acids regulate angiotensin peptides
production and consequently affect its pathophysiological functions in vivo? (2) Highly
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conserved regions of AGT were reported in our previous publication. The functions of
these conserved regions remain unclear. Do these highly conserved regions of AGT
determine its interaction with megalin, an AGT receptor expressing in renal proximal
tubule? Do these highly conserved regions of AGT influence AngII production and
atherosclerosis? Therefore, to address these questions, I aim to investigate the roles of
specific amino acids of AGT in AGT metabolism locally and systemically as well as
consequently AngII-mediated functions in this study.

1.6

Specific aims
To address some of the fundamental questions discussed above, I propose two

specific aims:
Aim 1: To investigate the role of two amino acids next to the renin cleavage site of AGT
in blood pressure and atherosclerosis (Chapter three).
Aim 2: To determine the effects of highly conserved regions of AGT on blood pressure
and atherosclerosis. (Chapter four).

Table 1-1 Nonstandard Abbreviations and Acronyms
Abbreviation
RAS

Renin angiotensin system

AGT

Angiotensinogen

AngI

Angiotensin I

AngII

Angiotensin II

ACE

Angiotensin-converting enzyme

AT1 receptor

Angiotensin II receptor type 1

hepAGT+/+ mice

Hepatocyte-specific AGT+/+ mice
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hepAGT-/- mice

Hepatocyte-specific AGT deficient mice

siRNAs

Small interfering RNAs

AAV

Adeno-associated virus

Null AAV

a null insertion in AAV

L11V;Y12I

Mouse AGT with replacement of the N-terminal
leucine at position 11 and tyrosine at position 12 to
valine and isoleucine, respectively

SPR

Surface plasmon resonance

WT.AAV

AAV encoding mouse wild type AGT

β-sheet.AAV

AAV encoding mouse AGT with the β-sheet mutations
at K253A, H274A, E422A

W292A.AAV

AAV encoding mouse AGT with the loop region
mutation at W292A

loop.AAV

AAV encoding mouse AGT with the loop region
mutations at W292A, S298A, V299A

loop deletion.AAV

AAV encoding mouse AGT with the loop region
mutations at whole conserved sequences which were
replaced by a GA linker

β-sheet and loop.AAV

AAV encoding mouse AGT with the β-sheet and loop
region mutations at K253A, H274A, E422A, W292A,
S298A, and V299A
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CHAPTER 2. GENERAL METHODS
This chapter describes the methods, including mouse blood collection, plasma total
cholesterol measurement, plasma AGT measurement, systolic blood pressure
measurement, quantification of atherosclerotic lesion sizes and statistical analysis, used in
studies in Chapter 3 and Chapter 4.

2.1

Materials
Reagents used in studies in Chapter 3 and 4 are listed below.

Table 2-1 Reagents and chemicals used in studies in Chapter 3 and 4.
Reagents
Vendor or Source
Catalog #
Cholesterol E for plasma total

Wako Chemicals USA

999-02601

IBL America

27413

IBL America

27412

cholesterol concentrations
Mouse total angiotensinogen (AGT)
ELISA
Human total angiotensinogen (AGT)
ELISA
Plasma and renal AngII

Attoquant Diagnostics

concentrations by liquid
chromatography–mass spectrometry
Mouse renin ELISA kit

R&D Systems

DY4277

DuoSet Ancillary Reagent Kit 2

R&D Systems

DY008

Angiotensin II

Bachem

H-1705

24

2.2

Plasma profiles
Mouse blood were collected in the presence of EDTA (final concentration: 1.8

mg/ml) and a proteinase inhibitor cocktail (provided by Attoquant Diagnostics GmbH,
Vienna, Austria) to prevent degradation of AGT and angiotensin peptides. During the
experiment, blood was collected through retro-orbital bleeding at selected intervals.
Cardiac bleeding via right ventricle was used to collect blood at termination.
Plasma total cholesterol concentrations were measured using an enzymatic
commercial kit (Cat # 999-02601; Wako Chemicals USA).
Plasma AGT concentrations were measured using a mouse AGT ELISA kit (Code
# 27413; IBL America) or a human AGT ELISA kit (Code # 27412; IBL America).
Plasma renin concentrations were measured using an ELISA kit (Mouse renin
ELISA kit, Cat # DY4277; R&D Systems).

2.3

Systolic blood pressure measurement
Systolic blood pressure was measured on conscious mice using a non-invasive tail-

cuff system (Coda 8, Kent Scientific Corporation) following our standard protocol [152].
Data were collected and analyzed based on 20 measurements of each mouse every day for
3 consecutive days. Mean systolic blood pressure of each mouse from the 3-day
measurements was used for data analysis.
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2.4

Quantification of atherosclerosis
An en face method was used to measure atherosclerotic lesions on the intimal

surface of the aorta following the recent AHA statement [153], as detailed in our standard
protocol posted on protocols.io (dx.doi.org/10.17504/protocols.io.bfy8jpzw) and reported
in our publications (a few examples.[57, 59, 154, 155]). Briefly, the aorta was dissected
and fixed in 10% neutrally buffered formalin overnight. The adventitial tissues were
removed, then the intimal surface was exposed by a longitudinal cut and pinned on a black
wax surface. Images of en face aortas were taken by a Nikon digital camera (Nikon digital
sight DS-Ri1) with a mm ruler for calibration. Lesions were traced manually in the region
from the junction of the myocardium (after the aortic root) to 3 mm distal from the left
subclavian artery using Nikon NIS-Elements software (NIS-Elements AR 5.11.00.) under
a dissecting microscope. One individual measured the lesion areas, and a senior staff
member who did not know the animal groups verified the measurements independently.
Lesion size was presented as percent lesion area as below:
Percent lesion area (%) =

2.5

𝐴𝑡ℎ𝑒𝑟𝑜𝑠𝑐𝑙𝑒𝑟𝑜𝑡𝑖𝑐 𝑙𝑒𝑠𝑖𝑜𝑛 (𝑚𝑚2 )
× 100
𝐼𝑛𝑡𝑖𝑚𝑎𝑙 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑡ℎ𝑒 𝑎𝑜𝑟𝑡𝑎 (𝑚𝑚2 )

Statistical analysis
Data are represented as means ± standard error of means (SEM). SigmaPlot version

14.0 (SYSTAT Software Inc.) was used for statistical analyses. To compare multiplegroup data, one-way ANOVA followed by Holm-Sidak method was used for normally
distributed variables that passed equal variance test. Kruskal-Wallis one-way ANOVA on
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Ranks followed by Dunn’s method was used for data that did not pass either normality or
equal variance test. P < 0.05 was considered statistically significant.
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CHAPTER 3. ROLE OF AMINO ACIDS ADJACENT TO RENIN CLEAVAGE SITE IN
ANGIOTENSINOGEN IN ANGIOTENSIN II-MEDIATED FUNCTIONS IN MICE
This chapter is based on our published article titled “The Two Amino Acids
Proximate to the Renin Cleavage Site in Angiotensinogen Do Not Affect Angiotensin IImediated Functions”, with Chia-Hua Wu as the first author (Arterioscler Thromb Vasc
Biol. 2020 Jul 9;ATVBAHA120314048. doi: 10.1161/ATVBAHA.120.314048.)

3.1

Abstract
Renin cleavage of angiotensinogen (AGT) has species specificity. Since the

residues at positions 11 and 12 are different between human AGT and mouse AGT, we
determined whether these two residues in AGT affect renin cleavage and angiotensin IImediated blood pressure regulation and atherosclerosis using an adeno-associated viral
(AAV) approach for manipulating AGT in vivo. Hepatocyte-specific AGT deficient
(hepAGT-/-) mice in an LDL receptor deficient background were infected with AAVs
containing a null insert, human AGT, or mouse AGT expressing the same residues of the
human protein at positions 11 and 12 [mouse AGT (L11V;Y12I)]. Expression of human
AGT in hepAGT-/- mice led to high plasma human AGT concentrations without changes
in plasma endogenous mouse AGT, plasma renin concentrations, blood pressure, or
atherosclerosis. This is consistent with human AGT not being cleaved by mouse renin. To
determine whether the residues at positions 11 and 12 in human AGT lead to the inability
of mouse renin to cleave human AGT, hepAGT-/- mice were injected with AAV encoding
mouse AGT (L11V;Y12I). Expression of mouse AGT (L11V;Y12I) resulted in increased
plasma mouse AGT concentrations, reduced renin concentrations, and increased renal
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AngII concentrations that were comparable to their concentrations in hepAGT+/+ mice.
This mouse AGT variant increased blood pressure and atherosclerosis in hepAGT-/- mice
to the magnitude of hepAGT+/+ mice. In conclusion, replacement of L11 and Y12 to V11
and I12, respectively, in mouse AGT does not affect renin cleavage, blood pressure, and
atherosclerosis in LDL receptor deficient mice.

3.2

Introduction
Renin cleavage of angiotensinogen (AGT) is the rate-limiting step in producing

bioactive angiotensin (Ang) peptides [61, 156]. The product of AGT and renin interaction
is AngI, the first 10 amino acids of the amino terminus of secreted AGT. AngI is highly
conserved from fly, rodents, to human [61]. One study reported that a conserved disulfide
bond between Cys18 and Cys138 in human AGT (Cys18 and Cys137 in mouse AGT)
regulated cleavage of human AGT by human renin in vitro [99]. However, our in vivo
study demonstrated that this conserved disulfide bond in AGT did not affect AngII
production and AngII-mediated functions [56], implicating potentially different results
from in vitro versus in vivo conditions.
Renin cleavage of AGT displays species specificity [157-159]. For example, human
AGT is not cleaved by mouse renin, and vice versa as demonstrated in transgenic mouse
models [158, 159]. Similarly, human AGT is not cleaved by canine renin, but replacement
of the residues at positions 11 and 12 of human AGT to the two residues in canine AGT
enhanced its cleavage by canine renin in an in vitro study [105], implicating that these two
residues adjacent to the renin cleavage site are important for regulating AGT cleavage by
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renin. However, it has not been determined whether the two amino acids adjacent to the
AngI sequence in AGT affect renin cleavage and AngII-mediated functions in vivo.
In this study, we used an adeno-associated viral vector (AAV)-driven expression
approach to either populate the full length of human AGT or mouse AGT that its two
residues at positions 11 and 12 were replaced with the two residues in the human protein.
This approach provided a rapid and efficient manipulation of AGT to study amino acid
determinants of its interaction with renin in vivo and the consequent AngII-mediated
physiological and pathophysiological functions such as such as blood pressure and
atherosclerosis.

3.3
3.3.1

Methods and materials
Animals
Development of hepatocyte-specific AGT deficient mice has been reported

previously [160-162]. AGT floxed (termed “Agt

”) x albumin-Cre-/- (hepAGT+/+) and

f/f

Agt f/f x albumin-Cre+/- (hepAGT-/-) littermates were used for experiments described in this
manuscript. Genotypes were determined prior to weaning and validated after termination
by Cre PCR and confirmed by measuring plasma AGT concentrations during the study
and after termination. Male and female mice in a low-density lipoprotein receptor (LDLR)/-

background were studied separately following the recent ATVB Council statement [163].

All animal experiments reported in this manuscript were performed with the approval of
the University of Kentucky Institutional Animal Care and Use Committee (IACUC
protocol number 2006-0009 or 2018-2968).
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3.3.2

Production and injection of adeno-associated viral (AAV) vector
AAV vectors (serotype 2/8) driven by a hepatocyte-specific thyroxine-binding

globulin (TBG) promoter were produced by the Vector Core in the Gene Therapy Program
at the University of Pennsylvania. Three AAV vectors were made: (1) a null insertion (null
AAV; used as control), (2) encoding the human AGT (human AGT.AAV), and (3)
encoding the mouse AGT with L11V;Y12I mutations (L11V;Y12I.AAV). The
L11V;Y12I represented that the N-terminal leucine at position 11 and tyrosine at position
12 in mouse AGT were replaced by valine and isoleucine, respectively, to mimic the two
amino acids at the same positions in human AGT (Figure 3.1A).

Figure 3.1 Experimental designs of AGT mutation and mouse experiment.
(A) N-terminal amino acids 1 - 10 (AngI) are the same between human and mouse AGT.
Amino acids at positions 11 and 12 are different between human and mouse AGT. Mouse
(L11V;Y12I) represent the N-terminal leucine at position 11 and tyrosine at position 12 in
mouse AGT replaced by valine and isoleucine, respectively, to mimic the two amino acids
at the same positions of human AGT. (B) Schematic summary of the experimental design:
LDL receptor -/- mice were injected intraperitoneally with AAVs encoding a null insert,
human AGT, or mouse AGT (L11V;Y12I). Two weeks after AAV injections, mice were
fed a Western diet for 12 weeks. Blood pressure was measured on week 10 during the
Western diet feeding, and atherosclerosis was measured after termination.
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All mice were fed a normal laboratory diet (Diet # 2918; Envigo), and were injected
intraperitoneally with AAV vectors (3 x 1010 genome copies/mouse). hepAGT+/+ mice
were injected with null AAV as a positive control at 8 - 12 weeks of age. Sex- and agematched hepAGT-/- mice were randomized to receive AAVs containing a null insert
(negative control), human AGT, or L11V;Y12I mouse AGT. Two weeks after injection,
to induce hypercholesterolemia, all study mice have been fed a Western diet (Diet #
TD.88137; Envigo) for 12 weeks (Figure 3.1B). This diet has high saturated fat, modest
cholesterol enrichment, and no cholate. The diet contents of this Western diet are shown
in the Table 3-1.
Table 3-1 The diet contents of Western diet
Contents

% by weight

% kcal

Protein

17.3

15.2

Carbohydrate

48.5

42.7

Fat

21.2

42.0

Cholesterol

0.2

3.3.3

Osmotic Mini Pump Implantation and Angiotensin II Infusion
Saline or angiotensin II (AngII 0.5 µg/kg/min; Cat# H-1706; Bachem) was infused

subcutaneously via mini osmotic pumps (Alzet Model # 2006; Durect Corp.) as described
in our publication. 5 Male hepAGT-/- mice were infused with either saline or AngII, and
their hepAGT+/+ littermates were infused with saline. Mice were sedated with isoflurane
and pumps were implanted subcutaneously on the right flank of each mouse. Incisions
were closed with surgical staples and a topical anesthetic cream (LMX4; Ferndale
Laboratories) was applied immediately after surgery to relieve pain.
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3.3.4

Plasma profiles
Methods of blood collection, and measurements of plasma total cholesterol and

plasma AGT were described in Chapter 2 General methods.
Plasma renin concentrations in male mice were measured using a radioimmunoassy
method: 5 Mouse plasma samples (8 μl) were incubated in an assay buffer (Na2HPO4 0.1
M, EDTA 0.02 M, maleate buffer pH 6.5, phenylmethyl-sulfonyl fluoride 2 μl; total
volume of 250 μl) with an excess of rat AGT at 37 ̊C for 30 min. The reaction was
terminated by placing samples at 100 ̊C for 5 min. AngI generated in each sample was
quantified by radioimmunoassay using a commercially available kit (Cat # 1553;
DiaSorin).
Plasma renin concentrations in female mice were measured using an ELISA kit
(Mouse renin ELISA kit, Cat # DY4277; R&D Systems). We compared plasma renin data
between male and female hepAGT+/+ and

-/-

mice side-by-side using this ELISA kit as

shown in Figure 3.2.

Plasma renin (ng/ml)

1200

hepAGT+/+

hepAGT-/-

1000
800
600
400
200
0
Male

Female

Male

Female

Figure 3.2 Plasma renin concentrations in hepAGT+/+ and hepAGT-/- male and
female mice measured using a mouse renin ELISA kit.
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3.3.5

Systolic blood pressure measurements
Systolic blood pressure measurement was described in Chapter 2 General methods.

3.3.6

Quantification of atherosclerosis
An en face method was described in Chapter 2 General methods.

3.3.7

Angiotensin II (AngII) Measurements
Plasma

and

renal

AngII

concentrations

were

measured

using

liquid

chromatography–mass spectrometry by Attoquant Diagnostics GmbH (Vienna, Austria).
All samples were assayed in a blinded manner.

3.3.8

Statistical analysis
Statistical analysis was described in Chapter 2 General methods.

3.4
3.4.1

Results
Population of human AGT in hepAGT -/- mice did not affect systolic blood
pressure and atherosclerosis
In both hepAGT+/+ and -/- male mice infected with null AAV, human AGT was not

detected in mouse plasma by ELISA. In hepAGT-/- mice infected with AAV encoding
human AGT, plasma human AGT concentrations were comparable to plasma AGT
concentrations of humans [164] (Figure 3.3A), but did not affect plasma concentrations of
endogenous mouse AGT (Figure 3.3B), demonstrating induction of human AGT did not
affect endogenous mouse AGT concentrations in hepAGT-/- mice. Plasma renin
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concentrations were comparable between hepAGT-/- mice infected with null AAV and
human AGT.AAV, both of which were higher than those in hepAGT+/+ mice injected with
null AAV (Figure 3.3C). Plasma total cholesterol concentrations were above 1,000 mg/dl
after 12 weeks of Western diet feeding with no differences among the 3 groups (Figure
3.3D). Since AngII, the major effector peptide of the renin-angiotensin system, regulates
blood pressure and contributes to development of atherosclerosis, we measured these two
parameters. Expression of human AGT in hepAGT-/- mice did not change systolic blood
pressure and atherosclerotic lesion size, when compared to hepAGT-/- mice infected with
null AAV (Figure 3.3E and F). However, systolic blood pressure and atherosclerotic lesion
size were much higher in hepAGT+/+ mice than in hepAGT-/- mice injected with either null
AAV or human AGT AAV. These findings were also confirmed in female mice (Figure
3.4), demonstrating that human AGT does not affect AngII-mediated functions in mice
irrespective of sex.
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Figure 3.3 Human AGT does not affect blood pressure and atherosclerosis in male
hepAGT-/- mice.
All study mice were in an LDL receptor-/- background. (A) Plasma human AGT
concentrations were measured by an ELISA kit that was specific for human AGT. *P<0.05
versus the other 2 groups by Kruskal–Wallis one-way ANOVA on Ranks with Dunn’s
method. (B) Plasma mouse AGT concentrations were measured by an ELISA kit that was
specifically targeting mouse AGT. *P<0.05 versus hepAGT+/+ mice injected with null
AAV by Kruskal–Wallis one-way ANOVA on Ranks with Dunn’s method. (C) Plasma
renin concentrations were measured by radioimmunoassay. *P<0.05 versus hepAGT+/+
mice injected with null AAV by Kruskal–Wallis one-way ANOVA on Ranks with Dunn’s
36

method. (D) Plasma total cholesterol concentrations were measured by an enzymatic assay
kit and analyzed with one-way ANOVA. P>0.05. (E) Systolic blood pressure was
measured using a tail-cuff system 3 weeks after AAV injection. *P<0.05 versus hepAGT+/+
mice injected with null AAV by one-way ANOVA with Holm-Sidak method. (F)
Atherosclerotic lesion area was quantified by an en face method. *P<0.05 versus
hepAGT+/+ mice injected with null AAV by one-way ANOVA with Holm-Sidak method.
N = 16 - 22/group. hepAGT+/+ mice: hepatocyte-specific AGT+/+ mice; hepAGT-/- mice:
hepatocyte-specific AGT deficient mice. hepAGT+/+ and hepAGT-/- study mice were
littermates. Mice were 18 - 24 weeks old at termination.
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Figure 3.4 Human AGT does not change blood pressure and atherosclerosis in
female hepAGT-/- mice.
All study mice were in an LDL receptor-/- background. Plasma human (A) and mouse (B)
AGT concentrations were measured by ELISA. *P<0.05 by Kruskal-Wallis one-way
ANOVA on Ranks with Dunn’s method. (C) Systolic blood pressure was measured using
a tail-cuff system. *P<0.05 by one-way ANOVA with Holm-Sidak method. (D)
Atherosclerotic lesion area was quantified by an en face method. *P<0.05 by one-way
ANOVA with Holm-Sidak method. N = 5 - 7/group. hepAGT+/+ mice: hepatocyte-specific
AGT+/+ mice; hepAGT-/- mice: hepatocyte-specific AGT deficient mice. hepAGT+/+ and
hepAGT-/- study mice were littermates. Mice were 22 – 31 weeks old at termination.

3.4.2

Expression of mouse AGT L11V;Y12I in hepAGT-/- mice normalized AngII
production and blood pressure, and augmented atherosclerosis
To determine whether N-terminal residues at positions 11 and 12 of AGT affect

renin cleavage, AAV encoding mouse AGT with the L11V and Y12I substitutions were
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injected into male hepAGT-/- mice with an LDL receptor-/- background. Administration of
mouse AGT(L11V;Y12I).AAV led to increased plasma mouse AGT concentrations to be
comparable as in hepAGT+/+ mice injected with null AAV (Figure 3.5A). Plasma renin
concentrations were not different between hepAGT+/+ mice and hepAGT-/- mice populated
with mouse AGT(L11V;Y12I), but lower than hepAGT-/- mice infected with null AAV
(Figure 3.5B). To confirm that increased plasma renin concentrations in hepAGT-/- were
due to lower AngII production, we infused either saline or AngII to male hepAGT-/- mice
and compared with their male hepAGT+/+ littermates infused with saline. Plasma renin
concentrations were much higher in hepAGT-/- mice infused with saline, compared with
their wild type littermates. Infusion of AngII in hepAGT-/- mice suppressed plasma renin
concentrations to the comparable concentrations as in hepAGT+/+ mice (Figure 3.6).

As reported previously [57], plasma AngII concentrations were not different
between hepAGT+/+ and hepAGT-/- mice, which were also not affected by infection of
AAVs encoding mouse AGT(L11V;Y12I) (Figure 3.5C). Renal AngII concentrations
were higher in hepAGT+/+ mice and hepAGT-/- mice infected with mouse
AGT(L11V;Y12I).AAV than in hepAGT-/- mice infected with null AAV (Figure 3.5D).
Plasma total cholesterol concentrations were not different among the 3 groups (Figure
3.5E). Population of mouse AGT(L11V;Y12I) in hepAGT-/- mice led to increased systolic
blood pressure (Figure 3.5F) and atherosclerotic lesion size (Figure 3.5G), which were
comparable to the two phenotypes in hepAGT+/+ mice infected with null AAV. A separate
study demonstrated that female hepAGT-/- mice with an LDL receptor-/- background
populated with mouse AGT(L11V;Y12I) had comparable blood pressure and
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atherosclerotic lesion size as female hepAGT+/+ mice injected with null AAV (Figure 3.7),
while their plasma cholesterol concentrations were not different (Figure 3.8).
Therefore, the amino-terminal amino acids at positions 11 and 12 of human AGT
that are adjacent to the renin cleavage site do not determine renal AngII production, blood
pressure, and atherosclerosis in mice irrespective of sex.
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Figure 3.5 Mouse AGT(L11V;Y12I) increases blood pressure and augmented
atherosclerosis in male hepAGT-/- mice.
All study mice were in an LDL receptor-/- background. (A) Plasma mouse AGT
concentrations were measured by ELISA. *P<0.05 versus the other 2 groups by Kruskal–
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Wallis one-way ANOVA on Ranks with Dunn’s method. (B) Plasma renin concentrations
were measured by radioimmunoassay. *P<0.05 versus the other 2 groups by Kruskal–
Wallis one-way ANOVA on Ranks with Dunn’s method. AngII concentrations in plasma
(C) and kidney (D) were measured using LC-MS/MS. *P<0.05 by Kruskal–Wallis oneway ANOVA on Ranks with Dunn’s method. (E) Plasma total cholesterol concentrations
were measured using an enzymatic kit and analyzed by one-way ANOVA. (F) Systolic
blood pressure was measured using a tail-cuff system. *P<0.05 versus the other 2 groups
by one-way ANOVA with Holm-Sidak method. (G) Atherosclerotic lesion area was
quantified by en face method. *P<0.05 versus the other 2 groups by one-way ANOVA with
Holm-Sidak method. N = 10 - 13/group. hepAGT+/+ mice: hepatocyte-specific AGT+/+
mice; hepAGT-/- mice: hepatocyte-specific AGT deficient mice. hepAGT+/+ and hepAGT/- study mice were littermates. Mice were 18 – 26 weeks old at termination.
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Figure 3.6 Infusion of AngII suppresses plasma renin concentrations in male
hepAGT-/- mice.
All study mice were in an LDL receptor-/- background. Plasma renin concentrations were
measured by ELISA. *P<0.05 by Kruskal-Wallis one-way ANOVA with Dunn's Method.
N = 6 - 7/group. hepAGT+/+ mice: hepatocyte-specific AGT+/+ mice; hepAGT-/- mice:
hepatocyte-specific AGT deficient mice. hepAGT+/+ and hepAGT-/- study mice were
littermates. Mice were 20 – 24 weeks old at termination.

42

Figure 3.7 Mouse AGT(L11V;Y12I) increases blood pressure and augmented
atherosclerosis in female hepAGT-/- mice.
All study mice were in an LDL receptor-/- background. (A) Plasma mouse AGT
concentrations were measured by ELISA. *P<0.05 by Kruskal-Wallis one-way ANOVA
on Ranks with Dunn’s method. (B) Plasma renin concentrations were measured by ELISA.
*P<0.001 by one-way ANOVA with Holm-Sidak method. (C) Systolic blood pressure was
measured using a tail-cuff system. *P<0.05 by one-way ANOVA with Holm-Sidak
method. (D) Atherosclerotic lesion area was quantified by an en face method. *P<0.05 by
one-way ANOVA with Holm-Sidak method. N = 5 - 11/group. hepAGT+/+ mice:
hepatocyte-specific AGT+/+ mice; hepAGT-/- mice: hepatocyte-specific AGT deficient
mice. hepAGT+/+ and hepAGT-/- study mice were littermates. Mice were 22 – 31 weeks old
at termination.
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Figure 3.8 Mouse AGT(L11V;Y12I) does not change plasma cholesterol
concentrations in female hepAGT-/- mice.
All study mice were in an LDL receptor-/- background. Plasma total cholesterol
concentrations were measured using an enzymatic kit and analyzed by one-way ANOVA.
N = 5 - 11/group. hepAGT+/+ mice: hepatocyte-specific AGT+/+ mice; hepAGT-/- mice:
hepatocyte-specific AGT deficient mice. hepAGT+/+ and hepAGT-/- study mice were
littermates. Mice were 22 – 31 weeks old at termination.

3.5

Discussion
Using an AAV approach for manipulating AGT in hepatocytes, this study reports

two novel findings. First, human AGT does not affect AngII-mediated blood pressure
regulation and atherosclerosis in LDL receptor-/- mice lacking endogenous AGT in
hepatocytes. Second, replacement of the amino-terminal amino acids at positions 11 and
12 of mouse AGT to mimic human AGT does not impair renin cleavage of AGT, resulting
in normal renal AngII production and AngII-mediated blood pressure regulation and
atherosclerosis.
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Previous studies using human AGT transgenic mice have demonstrated that the
presence of human AGT in mice does not affect systolic blood pressure [165-167]. In
human AGT transgenic mice, human AGT was expressed in mice with normal
concentrations of endogenous mouse AGT and relatively low mouse renin concentrations,
which does not rule out the possibility that lack of cleavage of human AGT is due to low
mouse renin concentrations. Our mouse model has several advantages: (1) We used a
mouse model having low endogenous mouse AGT concentrations but high mouse renin
concentrations. The low plasma concentrations of mouse AGT were sufficient to enable
normal growth and kidney development, but led to much lower blood pressure, compared
to their wild type littermates [56, 57, 59]. Therefore, this mouse model is relevant to
physiological regulation of the renin-angiotensin system. More importantly, our mouse
model can address the caveats raised above in previous studies. (2) Our mouse model was
on an LDL receptor-/- background, so we were able to study two different AngII-induced
physiologic and pathophysiologic functions, namely blood pressure and atherosclerosis.
(3) The AAV vector encoding human AGT with a hepatocyte-specific promoter led to
human AGT produced in hepatocytes, mimicking the normal processing of AGT
production in liver and secretion to the circulation [57, 135].
In hepAGT-/- mice infected with AAV containing human AGT, plasma human AGT
concentrations were above 10 μg/ml, which were 3 - 4-fold higher than plasma endogenous
mouse AGT concentrations in wild type mice. Although mouse plasma renin
concentrations were greatly elevated in hepAGT-/- mice compared with wild type mice due
to removal of AngII-mediated negative feedback, the presence of human AGT did not
correct plasma renin concentrations, elevate blood pressure, or contribute to the
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development of atherosclerosis. Therefore, expression of human AGT did not restore
AngII-mediated functions in hepAGT-/- mice, which supports the notion that human AGT
is not cleaved by mouse renin in vivo [157-159, 165]. These results confirm previous
findings of species specificity of AGT and renin interaction [157, 158, 168], and extend
these findings to the in vivo physiological and pathophysiological setting.
In contrast to population of human AGT in hepAGT-/- mice, population of mouse
AGT with L11 and Y12 being substituted to the residues of human AGT reduced plasma
renin concentrations and increased renal AngII concentrations to those of wild type mice.
As anticipated with these findings, the responses of blood pressure and atherosclerotic
lesion size were restored in hepAGT-/- mice infected with murine AGT containing these
two residues of human AGT. These findings provide compelling evidence that the two
amino acid substitutions between murine and human do not affect renin cleavage of AGT
and the subsequent AngII-mediated blood pressure regulation and atherosclerosis in
hepAGT-/- mice. Our results do not support a role for these two residues of human AGT
as determinants of the species-specificity of the reaction between AGT and renin.

Consistent with our previous report [57], plasma AngII concentrations were not
different between hepAGT+/+ and -/- mice, irrespective of infection with AAV containing
a null insert or mutated AGT. In contrast, population of mouse AGT with L11V;Y12I
substitutions increased renal AngII concentrations to levels of hepAGT+/+ mice, consistent
with changes of blood pressure and atherosclerosis in these mice. In this study, AngII
concentrations in kidney were considerably higher than in plasma. AT1a receptor is
abundant in kidney [169]. Indeed, previous studies have reported that expression of AT1a
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receptor in kidney, but not in the vasculature, contributes to blood pressure regulation by
AngII [170, 171]. Since renal AngII, but not plasma AngII, reflects AngII effects on blood
pressure regulation and atherosclerosis, these results suggest that local tissue AngII (e.g.
renal) is important in these effects of the renin-angiotensin system.
Plasma AGT concentrations in male hepAGT-/- mice injected AAV encoding
mouse AGT(L11V;Y12I) were compared to those in their hepAGT+/+ littermates. We
noted much lower plasma AGT concentrations in female hepAGT-/- mice injected AAV
encoding mouse AGT(L11V;Y12I) than in their hepAGT+/+ littermates. This sex
difference has also been reported in mice injected with AAV encoding PCSK9 [172, 173].
The mechanism responsible for this sex difference is unclear. Despite the lower plasma
AGT concentrations in female mice, mouse AGT(L11V;Y12I), but not human AGT,
increased both blood pressure and atherosclerosis in female hepAGT-/- mice to those of
their wild type littermates. These results support that the amino-terminal amino acids at
positions 11 and 12 of human AGT that are adjacent to the renin cleavage site do not
determine renal AngII production, blood pressure, and atherosclerosis in mice independent
of sex.
Infusion of AngII in hepAGT-/- mice suppressed plasma renin concentrations,
supporting that lower blood pressure and atherosclerosis in hepatocyte-specific deletion of
AGT are attributed to lower AngII concentrations. In future studies, we will determine
whether blockade of AT1 receptors would inhibit the increased blood pressure and
atherosclerosis in hepAGT-/- mice injected with AAVs encoding mouse AGT
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(L11V,Y12I), which would further support that AngII and AT1 receptor interaction is the
mechanism to blood pressure regulation and atherosclerosis in these mice.

Given the species-specificity of AGT cleavage by renin, we hypothesize that
differences of either other amino acid sequences or the tertiary protein structure of AGT
affect the renin cleavage. We therefore aligned AGT protein sequences from different
species and mapped highly conserved regions of surface residues onto the structure of the
AGT:renin complex that was published by Zhou et al. [99]. One conserved region of AGT
is anticipated to be in direct contact with renin and therefore expected to influence species
specific interaction between AGT and renin. Future studies will aim to manipulate nonconserved residues in this renin-interacting region to determine whether certain amino acid
sequences in this region affect the tertiary protein structure or interaction with renin.
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CHAPTER 4. ROLES OF CONSERVED SEQUENCES IN THE Β-SHEET AND LOOP REGIONS OF
ANGIOTENSINOGEN IN ANGIOTENSIN II-MEDIATED FUNCTIONS IN MICE
This chapter is based on a manuscript in preparation, titled “Conserved sequences
in the β-sheet and loop regions of angiotensinogen synergistically regulate plasma
angiotensinogen production and affect angiotensin II-mediated functions”, with Chia-Hua
Wu as the first author. Figures based on experiments conducted by others are listed here:
figure 4.1A was made by Dr. Craig Vander Kooi and data of figure 4.1B was provided by
Dr. Dudley Strickland.

4.1

Abstract
Angiotensinogen (AGT) is the only precursor of all angiotensin peptides. Our

previous publication shows that two highly conserved regions, the β-sheet and loop region
on the face of AGT distal to renin interacting face might have renin-independent functions.
In this study, we determined whether these highly conserved regions in AGT affect
angiotensin II-mediated blood pressure regulation and atherosclerosis using an adenoassociated viral (AAV) approach for manipulating AGT in vivo. Surface plasmon
resonance analysis showed that mutation of W292 in AGT loop region decreased its
binding affinity to megalin, a protein that is abundant in renal proximal convoluted tubules.
To determine whether mutation of W292A affected AngII-mediated functions in mice, we
used hepatocyte-specific AGT deficient (hepAGT-/-) mice in an LDL receptor deficient
background were infected with AAVs containing a null insert, WT AGT, or mouse AGT
with W292A mutation. Repopulation of this mutated AGT increased plasma AGT
concentrations, blood pressure, and atherosclerosis, to the magnitudes, which were

comparable to those in hepAGT+/+ mice. Subsequently, to determine whether triple
nucleotide mutations in the β-sheet or the loop region of AGT affect AngII-mediated
functions. Infection of AAVs encoding mutations K253A;H274A;E422A of the β-sheet
region or W297A;S303A;V304A of the loop region in hepAGT-/- mice increased plasma
AGT concentrations, blood pressure, and atherosclerosis to be equivalent as in hepAGT+/+
mice, supporting that the 3 conserved residues of each region do not affect AGT
metabolism and AngII-mediated functions. Next, we replaced the residues of 291-301 in
the loop region with a GA linker, and infected hepAGT-/- mice with AAVs encoding this
protein. Expression of this mutated AGT moderately increased plasma AGT
concentrations, but increased blood pressure and atherosclerosis to a level comparable to
hepAGT+/+ mice. We then determined whether conserved sequences in the β-sheet and
loop regions would have synergistic effects on AngII-mediated functions. Administration
of AAV encoding mutated sequences in both the β-sheet region (K253A;H274A;E422A)
and the loop region (W297A;S303A;V304A) did not increase plasma AGT concentrations,
blood pressure, or atherosclerosis in hepAGT-/- mice, supporting that the conserved
sequences of these two regions have synergistic effects on AGT metabolism and function.
In conclusion, the conserved sequences in the β-sheet and loop regions of AGT
synergistically regulate AGT protein metabolism and AngII-mediated functions.

4.2

Introduction
Angiotensinogen (AGT) is the only precursor of the renin angiotensin system

(RAS), which plays critical roles in physiological and pathological functions, such as
regulations of sodium/water homeostasis and blood pressure [1, 2]. AGT is a member of
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the serine-proteinase inhibitor (serpin) family, but it does not have the enzyme activity
[174, 175]. Intact mouse AGT without a signal peptide has 453 amino acids. The Nterminal 10-residues peptide, angiotensin I (Ang I), is cleaved by renin. The remaining
cleaved AGT protein, termed des(AngI)AGT, has 98% of the parent protein, which
biological functions remain unclear [61].
AGT is a key factor affecting AngII-mediated functions, including blood pressure
and atherosclerosis [56, 57, 59]. However, Lu et al. reported that repopulation of
des(AngI)AGT in hepatocyte-specific AGT knockout mice which have deficiency of
plasma AGT did not regulate AngII-mediated functions, such as blood pressure and
atherosclerosis. Interestingly, repopulation of des(AngI)AGT increased body weight gain,
liver weight and liver triglyceride content, showing other biological functions of
des(AngI)AGT [59].
Analysis of conservation in AGT shows several potential functional surface regions
in des(AngI)AGT by comparing the amino acid sequences in human, rat, mouse and
zebrafish and mapping the sequences onto the protein structure of AGT [59, 99]. The Nterminal AngI, important for production of other angiotensin peptides, is highly conserved
in species. There are other three unknown surface conserved regions having observed.
Interestingly, based on the region interacting with renin, one conserved region directly
interacts with renin and two other conserved regions, the β-sheet face (K253, H274, and
E422) and the loop region (residues 291-301) with strictly conserved hydrophobic residues
W292 and V299 along with S298, on the distal face of AGT [59]. Conserved regions of
AGT distal to renin-binding region might have renin-independent functions, such as the
interaction with other proteins, instead of interaction with renin.
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AGT is primarily synthesized in liver and delivered to kidney [134, 135]. The
uptake of AGT in kidney is mediated by megalin, a multiligand endocytic receptor
abundant in renal proximal tubules and regulates the homeostasis of the RAS in the kidney
[57, 138]. It has been found that renal AngII concentration is associated with the
development of atherosclerosis [56, 57, 59, 156], showing the important roles of the
interaction of AGT with megalin in AngII-mediated functions. How the interaction of
AGT with megalin is regulated is still unclear. We hypothesize that conserved regions of
AGT distal to renin-binding region determine its interaction with megalin and further
affect AngII-mediated functions. Therefore, in this study, we made several mutations on
the β-sheet face and loop region of AGT and repopulated mutated AGT by adenoassociated virous expression approach in hepatocyte-specific AGT deficient mice to
investigate the effects of conserved regions of AGT on AGT metabolism and AngIImediated functions.

4.3

Methods and materials

4.3.1

Surface plasmon resonance (SPR)
Surface plasmon resonance was performed by Dr. Dudley Strickland at the

University of Maryland. Briefly, binding of AGT (GenScript) to megalin was assessed
using a Biacore 3000 optical biosensor system (GE Healthcare Life Sciences). Full length
megalin was coupled to a Sensor Chip CM5 (BR-1003-99; GE Healthcare Life Sciences).
Various concentrations of AGT ligand in HBS-P Buffer supplemented with 1 mM Ca2+
was flowed over the surface of the megalin-coupled sensor chip at a rate of 20 µL/min at
25°C.
52

4.3.2

Animals
Development of hepatocyte-specific AGT deficient mice has been reported

previously [56, 57, 59]. AGT floxed (termed “Agt f/f”) x albumin-Cre-/- (hepAGT+/+) and
Agt f/f x albumin-Cre+/- (hepAGT-/-) littermates were used for experiments described in this
manuscript. Genotypes were determined by Cre PCR and confirmed by measuring plasma
AGT concentrations. Male and female mice in an LDL receptor-/- background were studied
separately following the recent ATVB Council statement [163]. All animal experiments
reported in this manuscript were performed with the approval of the University of
Kentucky Institutional Animal Care and Use Committee (IACUC protocol number 20060009 or 2018-2968).

4.3.3

Production and injection of adeno-associated viral (AAV) vector
AAV vectors (serotype 2/8) driven by a hepatocyte-specific thyroxine-binding

globulin (TBG) promoter were produced by the Vector Core in the Gene Therapy Program
at the University of Pennsylvania. Seven AAV vectors were made: (1) a null insertion (null
AAV; used as control), (2) encoding the mouse wild type AGT (WT.AAV), (3) encoding
the mouse AGT with the β-sheet mutations at K253A, H274A, E422A (β-sheet.AAV), (4)
encoding the mouse AGT with the loop region mutation at W292A (W292A.AAV), (5)
encoding the mouse AGT with the loop region mutations at W292A, S298A, V299A
(loop.AAV), (6) encoding the mouse AGT with the loop region mutations at whole
conserved sequences which were replaced by a GA linker (loop deletion.AAV), and (7)
encoding the mouse AGT with the β-sheet and loop region mutations at K253A, H274A,
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E422A, W292A, S298A, and V299A (β-sheet and loop.AAV) (Fig. 4.1A). The W292A
represents the replacement of N-terminal tryptophan at position 292 to alanine in mouse
AGT. The triple mutation in the loop region (W292A;S298A;V299A) represents that
tryptophan at position 292, serine at position 298 and valine at position 299 were replaced
by alanine, respectively in mouse AGT. The loop deletion represents that an amino acid
sequence from tryptophan 292 to valine 299 was replaced by a GA linker, which stabilized
the protein structure. The triple mutation in the β-sheet (K253A;H274A;E422A) represents
that lysine at position 253, histidine at position 274 and glutamic acid at 422 were replaced
by alanine, respectively in mouse AGT. The double mutations in the β-sheet and loop
region (K253A;H274A;E422A;W292A;S298A;V299A) represent that the combination of
the triple mutations in the β-sheet and the triple mutations in the loop region in mouse
AGT.
All mice were fed a normal laboratory diet (Diet # 2918; Envigo), and were injected
intraperitoneally with AAV vectors (3 x 1010 genome copies/mouse). hepAGT+/+ mice
were injected with null AAV as a positive control at 8 - 12 weeks of age. Sex- and agematched hepAGT-/- mice were randomized to receive AAVs containing a null insert
(negative control), WT AGT, mutated mouse AGT with the β-sheet, mutated mouse AGT
with W292A, mutated mouse AGT with the loop mutation, mutated mouse AGT with loop
deletion mutation, or mutated mouse AGT with the β-sheet and loop mutations. Two
weeks after AAV injection, to induce hypercholesterolemia, all study mice have been fed
a Western diet (Envigo, Diet # TD.88137) for 12 weeks. The diet contents of this Western
diet are shown in the Table 3-1.
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4.3.4

Plasma profiles
Methods of blood collection, and measurements of plasma total cholesterol, plasma

AGT and plasma renin were described in Chapter 2 General methods.

4.3.5

Systolic blood pressure measurements
Systolic blood pressure measurement was described in Chapter 2 General methods.

4.3.6

Quantification of atherosclerosis
An en face method was described in Chapter 2 General methods.

4.3.7

Body composition
Body composition, including whole body fat mass, lean tissue mass, free water, and

total body water, was measured on conscious mice with EchoMRI-100™ (Echo Medical
Systems, Houston, TX, USA).

4.3.8

RNA isolation and quantitative PCR
Total RNA in liver was extracted with a commercial kit (Cat # AS1280;Promega)

configured with an automated Maxwell 16 purification system (Promega). To quantitate
mRNA abundance, total RNA was reversely transcribed with an iScript™ cDNA
Synthesis Kit (Cat #170-8891; Bio-Rad, Hercules, CA, USA), and quantitative PCR
(qPCR) was performed to quantify mRNA abundance using an SsoFast™ EvaGreen®
Supermix kit (Cat # 172-5204; Bio-Rad) on a Bio-Rad CFX96 cycler. Data were analyzed
using ∆∆Ct method and normalized by a geometric mean of internal controls including α-
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actin, GAPDH and RPLP2. Primers used for AGT are 5’-CTGACCCAGTTCTTGCCAC
and 5’-AACCTCTCATCGTTCCTTGG.

4.3.9

Statistical analysis
Statistical analysis was described in Chapter 2 General methods.

4.4
4.4.1

Results
The loop region of AGT might determine the interaction with megalin
The interaction of AGT and megalin predisposes to atherosclerosis [57]. To

investigate whether the loop region of AGT determines the interaction with megalin, we
analyzed the protein-protein interaction by surface plasmon resonance (SPR). A single
nucleotide mutation W292A on the loop region of AGT decreased the binding affinity of
AGT to megalin (Fig. 4.1B), suggesting that the loop region of AGT affects its binding to
megalin.
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Figure 4.1 Single nucleotide mutation on the loop region (W292A) decreases the
binding affinity of AGT to megalin.
(A) Structural analysis of highly conserved regions in des(Ang I) AGT based on
bioinformatic analyses of AGT gene sequences from human, rat, mouse, and zebrafish.
Four highly conserved surface regions (Core, renin interacting, βsheet face, and loop) were
identified in des(AngI) AGT domain. (B) Protein-protein interactions between AGT and
megalin analyzed by SPR.
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4.4.2

W292 in the loop region does not affect AGT metabolism and AngII-mediated
functions.
Then, we determined whether W292A mutation in the loop region of AGT affects

AngII-mediated functions. Expression of AGT with W292A (Fig. 4.2A) significantly
increased plasma AGT concentration in hepAGT-/- mice (Fig. 4.2B), showing that W292A
of AGT does not affect AGT expression and synthesis. Plasma renin concentration acts as
an indirect indicator of plasma AngII concentration because of negative feedback
regulation of AngII production. HepAGT-/- mice repopulated with W292 AGT
significantly decreased plasma renin concentration which level was comparable with
hepAGT+/+ mice injected with null AAV and hepAGT-/- infected with WT.AAV (Fig.
4.2C). Mice body weights were measured weekly to monitor their general health.
HepAGT-/- mice have less body weight and fat mass gains during 12-weeks western diet
feeding (Fig. 4.3 A and B), which is consistent to our previous findings [59]. HepAGT-/infected with W292A AGT did not show significant difference in weekly body weight and
fat mass gains compared to hepAGT+/+ mice injected with null AAV and hepAGT-/injected with WT.AAV (Fig. 4.3A and B). There was no significant difference in plasma
total cholesterol concentrations among groups (Fig. 4.3C). Since blood pressure and
development of atherosclerosis are regulated by AngII, the major bioactive peptide of the
classical renin-angiotensin system, we measured these two parameters to investigate
whether mutated AGT affects blood pressure and atherosclerosis. HepAGT-/- mice
expressing W292A AGT displayed significantly higher systolic blood pressure and
atherosclerotic lesion size than those in hepAGT-/- mice injected with null AAV.
Moreover, hepAGT-/- mice infected with this mutated AGT did not show significantly
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change in systolic blood pressure and atherosclerotic lesion size, compared to hepAGT+/+
mice infected with null AAV and hepAGT-/- mice infected with WT.AAV (Fig. 4.2D and
E), demonstrating that AGT with W292A mutation does not affect AngII-mediated
functions in mice.

Figure 4.2 Single nucleotide mutation (W292) on the loop region does not affect
AngII-mediated functions in male hepAGT-/- mice.
All study mice were in an LDL receptor-/- background. (A) Nucleotide mutation on the loop
region (B) Plasma mouse AGT concentrations were measured by a mouse AGT ELISA kit.
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*P<0.05 by Kruskal–Wallis one-way ANOVA on Ranks with Dunn’s method. (C) Plasma
renin concentrations were measured by radioimmunoassay. *P<0.05 by Kruskal-Wallis
one-way ANOVA on Ranks with Dunn’s method. (D) Systolic blood pressure was
measured using a tail-cuff system 9 weeks after AAV injection. *P<0.05 by one-way
ANOVA with Holm-Sidak method. (E) Atherosclerotic lesion area was quantified by an
en face method. *P<0.05 by one-way ANOVA with Holm-Sidak method. N = 5 - 8/group.
hepAGT+/+ mice: hepatocyte-specific AGT+/+ mice; hepAGT-/- mice: hepatocyte-specific
AGT deficient mice. hepAGT+/+ and hepAGT-/- study mice were littermates. Mice were 22
– 31 weeks old at termination. Mice were 22 – 28 weeks old at termination.

Figure 4.3 W292A on the loop region in AGT does not affect body weight, lean and
fat mass as well as plasma total cholesterol in male hepAGT-/- mice.
All study mice were in an LDL receptor-/- background. (A) Weekly body weights in 16
weeks. (B) Lean mass and fat mass gains after 12 weeks western diet feeding. (C) Plasma
total cholesterol concentrations were measured by an enzymatic assay kit and analyzed
with one-way ANOVA. P>0.05. N = 5 - 8/group. hepAGT+/+ mice: hepatocyte-specific
AGT+/+ mice; hepAGT-/- mice: hepatocyte-specific AGT deficient mice. hepAGT+/+ and
hepAGT-/- study mice were littermates. Mice were 22 – 28 weeks old at termination.
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4.4.3

Three nucleotides in the β-sheet and loop regions, respectively, do not affect AGT
metabolism and AngII-mediated functions.
In hepAGT-/- mice infected with AAV encoding mutated AGT with triple

nucleotide mutations (K253A;H274A;E422A) on the β-sheet region (Fig. 4.4A), plasma
AGT concentrations were comparable to plasma AGT concentrations in hepAGT+/+ mice
infected with null AAV and hepAGT-/- infected with WT AGT.AAV (Fig. 4.4B),
demonstrating that triple nucleotide mutations on the β-sheet did not affect AGT
production. Plasma renin concentrations were comparable between hepAGT-/- mice
infected with β-sheet.AAV and hepAGT+/+ mice injected with null AAV, both of which
were lower than those in hepAGT-/- mice injected with null AAV (Fig. 4.4C). Repopulation
of mutated AGT with the β-sheet mutation did not affect weekly body weight and fat mass
gains, compared to hepAGT+/+ mice injected with null AAV and hepAGT-/- mice infected
with WT.AAV (Fig. 4.5A and B). There was no significant difference in plasma total
cholesterol concentrations among groups (Fig. 4.5C). Expression of AGT with the β-sheet
mutation in hepAGT-/- mice had increased systolic blood pressure and atherosclerotic
lesion sizes which were comparable to hepAGT+/+ mice infected with null AAV and
hepAGT-/- mice infected with WT.AAV (Fig. 4.4D and E), demonstrating that AGT with
the β-sheet mutation does not affect AngII-mediated functions in mice.

61

Figure 4.4 Triple nucleotide mutations on the β-sheet in AGT do not affect AngIImediated functions in male hepAGT-/- mice.
All study mice were in an LDL receptor-/- background. (A) Nucleotide mutations on the βsheet (B) Plasma mouse AGT concentrations were measured by a mouse AGT ELISA kit.
*P<0.05 by one-way ANOVA with Holm-Sidak method. (C) Plasma renin concentrations
were measured by radioimmunoassay. *P<0.05 by Kruskal-Wallis one-way ANOVA on
Ranks with Dunn’s method. (D) Systolic blood pressure was measured using a tail-cuff
system 9 weeks after AAV injection. *P<0.05 by one-way ANOVA with Holm-Sidak
method. (E) Atherosclerotic lesion area was quantified by an en face method. *P<0.05 by
one-way ANOVA with Holm-Sidak method. N = 3 - 6/group. hepAGT+/+ mice:
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hepatocyte-specific AGT+/+ mice; hepAGT-/- mice: hepatocyte-specific AGT deficient
mice. hepAGT+/+ and hepAGT-/- study mice were littermates. Mice were 18 – 32 weeks old
at termination.

Figure 4.5 Triple nucleotide mutations on the β-sheet in AGT do not affect body
weight, plasma total cholesterol as well as lean and fat mass in male hepAGT-/- mice.
All study mice were in an LDL receptor -/- background. (A) Weekly body weights in 12
weeks. (B) Lean mass and fat mass gains after 12 weeks western diet feeding. (C) Plasma
total cholesterol concentrations were measured by an enzymatic assay kit and analyzed
with one-way ANOVA. P>0.05. N = 3 - 6/group. hepAGT+/+ mice: hepatocyte-specific
AGT+/+ mice; hepAGT-/- mice: hepatocyte-specific AGT deficient mice. hepAGT+/+ and
hepAGT-/- study mice were littermates. Mice were 18 – 32 weeks old at termination.
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We investigated whether three nucleotide mutations in the loop region (W292A,
S298A, V299A) of AGT (Fig. 4.6A) affect AGT production and AngII-mediated
functions. Expression of AGT with triple nucleotide mutations on the loop region did not
significantly change plasma AGT concentrations, compared to plasma AGT
concentrations in hepAGT+/+ mice infected with null AAV and hepAGT-/- infected with
WT AGT.AAV (Fig. 4.6B). Plasma renin concentrations were comparable between
hepAGT-/- mice infected with loop.AAV, hepAGT-/- mice infected with WT AGT.AAV
and hepAGT+/+ mice, all of which were lower than those in hepAGT-/- mice injected with
null AAV (Fig. 4.6C). HepAGT-/- mice infected with this mutated AGT did not show
significant difference in body weight and fat mass gains compared to WT controls (Fig.
4.7A and B). Also, plasma total cholesterol concentrations of hepAGT-/- mice infected with
loop.AAV were not significantly different from WT controls, although they were higher
than those in hepAGT-/- injected with null AAV (Fig. 4.7C). Repopulation of this mutated
AGT did not significantly change systolic blood pressure and atherosclerosis, compared
to hepAGT+/+ mice infected with null AAV and hepAGT-/- infected with WT AGT.AAV
(Fig. 4.6D and E). Taken together, three residues in the β-sheet and loop region,
respectively, are not critical for AGT metabolism and consequently AngII-mediated
functions.
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Figure 4.6 Triple nucleotide mutations on the loop region in AGT do not affect
AngII-mediated functions in male hepAGT-/- mice.
All study mice were in an LDL receptor-/- background. (A) Nucleotide mutations on the
loop region (B) Plasma mouse AGT concentrations were measured by a mouse AGT
ELISA kit. *P<0.05 by one-way ANOVA with Holm-Sidak method. (C) Plasma renin
concentrations were measured by radioimmunoassay. *P<0.05 by Kruskal-Wallis one-way
ANOVA on Ranks with Dunn’s method. (D) Systolic blood pressure was measured using
a tail-cuff system 9 weeks after AAV injection. *P<0.05 by one-way ANOVA with HolmSidak method. (E) Atherosclerotic lesion area was quantified by an en face method.
*P<0.05 by one-way ANOVA with Holm-Sidak method. N = 7 - 10/group. hepAGT+/+
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mice: hepatocyte-specific AGT+/+ mice; hepAGT-/- mice: hepatocyte-specific AGT
deficient mice. hepAGT+/+ and hepAGT-/- study mice were littermates. Mice were 20 – 34
weeks old at termination.

Figure 4.7 Triple nucleotide mutations on the loop region do not affect body weight,
plasma total cholesterol as well as lean and fat mass in male hepAGT-/- mice.
All study mice were in an LDL receptor-/- background. (A) Weekly body weights in 12
weeks. (B) Lean mass and fat mass gains after 12 weeks western diet feeding. *P<0.05 by
one-way ANOVA with Holm-Sidak method. (C) Plasma total cholesterol concentrations
were measured by an enzymatic assay kit. *P<0.05 by one-way ANOVA with Holm-Sidak
method. N = 7 - 10/group. hepAGT+/+ mice: hepatocyte-specific AGT+/+ mice; hepAGT-/mice: hepatocyte-specific AGT deficient mice. hepAGT+/+ and hepAGT-/- study mice were
littermates. Mice were 20 – 34 weeks old at termination.
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4.4.4

Expression of mutated AGT with loop deletion in hepAGT-/- mice moderately
affects AGT production but does not affect AngII-mediated functions.
We then investigated whether replacement of the residues of 291-301 in the loop

region with a GA linker (Fig. 4.8A) affects AGT metabolism and AnII-mediated functions
in hepAGT-/- mice infected with loop deletion.AAV. HepAGT-/- mice infected with
loop.deletion AAV moderately increased plasma AGT concentrations, compared to
hepAGT+/+ mice injected with null AAV (Fig. 4.8B), showing that the whole conserved
sequence replacement in the loop region moderately affects AGT production. Liver mRNA
abundance of AGT in hepAGT-/- infected with loop deletion.AAV was not significantly
different from hepAGT+/+ mice injected with null AAV (Fig. 4.9A), suggesting that this
mutation does not affect expression of AGT. In hepAGT-/- mice infected with AAVs
encoding this protein, plasma renin concentration (131.4 ± 18.1 ng/ml) significantly
increased compared to hepAGT+/+ injected with null AAV (39.3 ± 3.7 ng/ml) (Fig. 4.8C).
Although there was no significant difference in plasma renin concentration between
hepAGT-/- mice infected with loop deletion.AAV and hepAGT-/- mice injected with null
AAV (482.9 ± 154.9 ng/ml), plasma renin concentrations of hepAGT-/- mice infected with
loop deletion.AAV were about 3.5 times lower than plasma renin concentrations of
hepAGT-/- mice injected with null AAV (Fig. 4.8C), suggesting that systemic AngII
concentrations were higher in hepAGT-/- mice infected with loop deletion.AAV than in
hepAGT-/- mice injected with null AAV. HepAGT-/- mice infected with this mutated AGT
did not show significant difference in body weight and fat mass gains compared to WT
controls (Fig. 4.9B and C). Plasma total cholesterol concentrations were not significantly
different among groups (Fig. 4.9D). For AngII-mediated functions, expression of AGT
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with the loop deletion mutation still significantly increased systolic blood pressure and
atherosclerosis compared to hepAGT+/+ mice injected with null AAV (Fig. 4.8D and E).
A separate female mice study demonstrated that female hepAGT-/- mice with an LDL
receptor-/- background populated with mutated AGT with loop deletion had comparable
blood pressure and atherosclerotic lesion size as female hepAGT+/+ mice injected with null
AAV, while their body weight and fat mass gains did not change (Fig. 4.10). In summary,
replacement of the whole conserved sequences of the loop region with a GA linker does
not affect blood pressure and atherosclerosis.
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Figure 4.8 GA linker substitution on the loop region in AGT decreases plasma AGT
concentration but did not affect AngII-mediated functions in male hepAGT-/- mice.
All study mice were in an LDL receptor-/- background. (A) Nucleotide mutation on the loop
region (B) Plasma mouse AGT concentrations were measured by a mouse AGT ELISA kit.
*P<0.05 by Kruskal–Wallis one-way ANOVA on Ranks with Dunn’s method. (C) Plasma
renin concentrations were measured by radioimmunoassay. *P<0.05 by Kruskal-Wallis
one-way ANOVA on Ranks with Dunn’s method. (D) Systolic blood pressure was
measured using a tail-cuff system 9 weeks after AAV injection. *P<0.05 by one-way
ANOVA with Holm-Sidak method. (E) Atherosclerotic lesion area was quantified by an
en face method. *P<0.05 by one-way ANOVA with Holm-Sidak method. N = 6 - 7/group.
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hepAGT+/+ mice: hepatocyte-specific AGT+/+ mice; hepAGT-/- mice: hepatocyte-specific
AGT deficient mice. hepAGT+/+ and hepAGT-/- study mice were littermates. Mice were 18
– 20 weeks old at termination.

Figure 4.9 GA linker substitution on the loop region in AGT does not affect mRNA
abundance, body weight, lean and fat mass as well as plasma total cholesterol in
male hepAGT-/- mice.
All study mice were in an LDL receptor-/- background. (A) mRNA abundance of liver
AGT. *P<0.05 by Kruskal–Wallis one-way ANOVA on Ranks with Dunn’s method. (B)
Weekly body weights in 12 weeks. (C) Lean mass and fat mass gains after 12 weeks
western diet feeding. *P<0.05 by one-way ANOVA with Holm-Sidak method. (D) Plasma
total cholesterol concentrations were measured by an enzymatic assay kit and analyzed
with one-way ANOVA. P>0.05. N = 6 - 7/group. hepAGT+/+ mice: hepatocyte-specific
AGT+/+ mice; hepAGT-/- mice: hepatocyte-specific AGT deficient mice. hepAGT+/+ and
hepAGT-/- study mice were littermates. Mice were 18 – 20 weeks old at termination.
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Figure 4.10 GA linker substitution on the loop region in AGT did not affect growth
and AngII-mediated functions in female hepAGT-/- mice.
All study mice were in an LDL receptor-/- background. (A) Weekly body weights in 12
weeks. (B) Lean mass and fat mass gains after 12 weeks western diet feeding. *P<0.05 by
Kruskal-Wallis one-way ANOVA on Ranks with Dunn’s method. (C) Plasma total
cholesterol concentrations were measured by an enzymatic assay kit and analyzed with
one-way ANOVA. P>0.05. (D) Systolic blood pressure was measured using a tail-cuff
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system 9 weeks after AAV injection. *P<0.05 by one-way ANOVA with Holm-Sidak
method. (E) Atherosclerotic lesion area was quantified by an en face method. *P<0.05 by
one-way ANOVA with Holm-Sidak method. N = 6 - 10/group. hepAGT+/+ mice:
hepatocyte-specific AGT+/+ mice; hepAGT-/- mice: hepatocyte-specific AGT deficient
mice. hepAGT+/+ and hepAGT-/- study mice were littermates. Mice were 18 – 28 weeks old
at termination.

4.4.5

Repopulation of AGT with mutations on the β-sheet and loop region in hepAGT-/mice affects AGT production and AngII-mediated functions.
We then determined whether conserved sequences in the β-sheet and loop regions

would have synergistic effects on AngII-mediated functions. Administration of AAV
encoding mutated sequences in both the β-sheet region (K253A;H274A;E422A) and the
loop region (W297A;S303A;V304A) (Fig. 4.11A) did not increase plasma AGT
concentrations, compared to hepAGT-/- mice injected with null AAV (Fig. 4.11B).
Although mRNA abundance of liver AGT in hepAGT-/- mice infected with β-sheet and
loop.AAV was significantly lower than hepAGT+/+ mice injected with null AAV, it was
higher than hepAGT-/- mice injected with null AAV (Fig. 4.12A), suggesting that the βsheet and loop region mutation might affect AGT synthesis in liver. Plasma renin
concentrations of hepAGT-/- mice infected with β-sheet and loop.AAV significantly
increased compared to WT controls (Fig. 4.11C). Body weight and fat mass gains were
decreased (Fig. 4.12B and C). Plasma total cholesterol concentrations were not
significantly different among groups (Fig. 4.12D). Administration of AGT with the β-sheet
and loop region mutation did not increase systolic blood pressure and atherosclerosis
compared to hepAGT-/- mice injected with null AAV (Fig. 4.11D and E). A separate
female mice study demonstrated that female hepAGT-/- mice with an LDL receptor-/background populated with AGT with mutations on the β-sheet and loop region had
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significantly decreased blood pressure and atherosclerotic lesion size as female hepAGT/-

mice injected with null AAV, while their body weight and fat mass gains also decreased

(Fig. 4.13). In summary, the β-sheet and loop region synergistically regulate AGT
metabolism and then consequently AngII-mediated functions in both male and female
mice.
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Figure 4.11 Mutations on the β-sheet (K253A, H274A, E422A) and loop region
(W292A, S298A, V299A) of AGT decrease plasma AGT concentration and affect
AngII-mediated functions in male hepAGT-/- mice.
All study mice were in an LDL receptor-/- background. (A) Nucleotide mutations on the βsheet and loop region (B) Plasma mouse AGT concentrations were measured by a mouse
AGT ELISA kit. *P<0.05 by Kruskal–Wallis one-way ANOVA on Ranks with Dunn’s
method. (C) Plasma renin concentrations were measured by radioimmunoassay. *P<0.05
by Kruskal-Wallis one-way ANOVA on Ranks with Dunn’s method. (D) Systolic blood
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pressure was measured using a tail-cuff system 9 weeks after AAV injection. *P<0.05 by
Kruskal-Wallis one-way ANOVA on Ranks with Dunn’s method. (E) Atherosclerotic
lesion area was quantified by an en face method. *P<0.05 by one-way ANOVA with HolmSidak method. N = 7 - 10/group. hepAGT+/+ mice: hepatocyte-specific AGT+/+ mice;
hepAGT-/- mice: hepatocyte-specific AGT deficient mice. hepAGT+/+ and hepAGT-/- study
mice were littermates. Mice were 18 – 20 weeks old at termination.

Figure 4.12 Mutations on the β-sheet (K253A, H274A, E422A) and loop region
(W292A, S298A, V299A) of AGT do not affect body weight, plasma total cholesterol
as well as lean and fat mass in male hepAGT-/- mice.
All study mice were in an LDL receptor-/- background. (A) mRNA abundance of liver
AGT. *P<0.05 by Kruskal-Wallis one-way ANOVA on Ranks with Dunn’s method. (B)
Weekly body weights in 12 weeks. (C) Lean mass and fat mass gains after 12 weeks
western diet feeding. *P<0.05 by one-way ANOVA with Holm-Sidak method. (D) Plasma
total cholesterol concentrations were measured by an enzymatic assay kit and analyzed
with one-way ANOVA. P>0.05. N = 7 - 10/group. hepAGT+/+ mice: hepatocyte-specific
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AGT+/+ mice; hepAGT-/- mice: hepatocyte-specific AGT deficient mice. hepAGT+/+ and
hepAGT-/- study mice were littermates. Mice were 18 – 20 weeks old at termination.

Figure 4.13 Mutations on the β-sheet (K253A, H274A, E422A) and loop region
(W292A, S298A, V299A) of AGT decrease plasma AGT concentration and affect
AngII-mediated functions in female hepAGT-/- mice.
All study mice were in an LDL receptor-/- background. (A) Plasma mouse AGT
concentrations were measured by a mouse AGT ELISA kit. *P<0.05 by Kruskal–Wallis
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one-way ANOVA on Ranks with Dunn’s method. (B) Plasma renin concentrations were
measured by radioimmunoassay. *P<0.05 by Kruskal-Wallis one-way ANOVA on Ranks
with Dunn’s method. (C) Weekly body weights in 12 weeks. (D) Lean mass and fat mass
gains after 12 weeks western diet feeding. (E) Systolic blood pressure was measured using
a tail-cuff system 9 weeks after AAV injection. *P<0.05 by Kruskal-Wallis one-way
ANOVA on Ranks with Dunn’s method. (F) Atherosclerotic lesion area was quantified by
an en face method. *P<0.05 by one-way ANOVA with Holm-Sidak method. N = 9 11/group. hepAGT+/+ mice: hepatocyte-specific AGT+/+ mice; hepAGT-/- mice:
hepatocyte-specific AGT deficient mice. hepAGT+/+ and hepAGT-/- study mice were
littermates. Mice were 19 – 31 weeks old at termination.

4.5

Discussion
This study reports three novel findings. First, the loop region might determine the

interaction of AGT with megalin. Secondly, mutation on each β-sheet or loop region of
AGT does not affect AGT function and AngII-mediated functions. Thirdly, the β-sheet
and loop region of AGT synergistically regulate AGT synthesis and consequently AngIImediated functions.
The β-sheet and loop region, highly conserved amino acids on the surface of AGT
which are distal to renin interacting face, were firstly reported in our previous publication
[59]. Lu et al. reported that these conserved regions in des(AngI)AGT might have
important roles in the regulation of AGT functions. Moreover, our previous publication
demonstrates the critical roles of AGT and megalin in renal RAS homeostasis and
atherosclerosis [57]. Therefore, in this study, firstly, we tested the protein-protein
interaction of W292A AGT and megalin. We found that the loop region of AGT affected
its binding to megalin (Fig. 4.1B). However, expression of W292A AGT in hepAGT-/mice did not affect systolic blood pressure and atherosclerosis (Fig. 4.2). We further
investigated the effects of the β-sheet and loop region on AGT metabolism and AnII77

mediated functions by several different mutations. Triple nucleotide mutations on the βsheet did not affect AGT production and blood pressure as well as atherosclerosis (Fig.
4.4), indicating that the β-sheet is not critical for regulation of AGT synthesis. However,
the β-sheet synergistically regulated AGT production and consequently AngII-mediated
functions with the loop region (Fig. 4.11). Triple nucleotide mutations on the loop region
did not affect AGT synthesis and AngII-mediated functions (Fig. 4.6). Expression of
replacement of whole conserved sequence of the loop region with a GA linker in hepAGT/-

mice showed the reduced plasma AGT concentration without changing blood pressure

or atherosclerosis, compared to hepAGT+/+ mice injected with null AAV or hepAGT-/mice infected with WT.AAV (Fig. 4.8), implicating that the loop region of AGT is
involved in the regulation of AGT synthesis. Interestingly, combination of triple
nucleotide mutations on both β-sheet and loop region showed the most profound effects
on AGT synthesis and abolished AngII-mediated functions (Fig. 4.11). Studies of
functions of des(AngI)AGT are limited. Des(AngI)AGT has been reported to inhibit
angiogenesis [107, 176]. Des(AngI)AGT can form high molecule AGT by RCL(reactive
center loop)-β-sheet polymerization [177], which is associated with pre-eclampsia [178,
179]. These studies reveal the other important roles of des(AngI)AGT in
pathophysiological functions. In this study, we demonstrate that highly conserved
sequences, the β-sheet and loop region of AGT regulate AGT functions and the loop region
affect the binding of AGT to megalin.
Lu et al. demonstrated that des(AngI)AGT, a conserved serpin domain of AGT,
exert an AngII-independent functions, such as body weight gain, liver weight, and liver
triglyceride content [59]. How des(AngI)AGT increases body weight gain, liver
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triglyceride content and liver weight remain unclear. In this study, we observed that
mutations on these highly conserved sequences did not change fat mass or body weight
gain compared to WT controls, showing that the β-sheet or the loop region are not essential
for the regulation of body weight and fat mass gains in mice fed a Western diet.
It has been shown that leukocytes-specific components of the RAS are not critical
for atherosclerosis, although leukocytes are involved in the pathogenesis of
atherosclerosis. For example, deficiency of AGT [59] or AT1 receptor [18] in bone
marrow-derived cells did not affect atherosclerosis. Moreover, AngII concentration and
AT1 receptor expression are predominant in kidney, revealing the potential pivotal roles
of renal RAS in atherosclerosis. AGT and megalin interactions contribute to renal RAS
homeostasis and atherosclerosis. In this study, we investigated how AGT and megalin
interaction regulates AngII-mediated functions. However, there are some difficulties
limiting the explores of interactions of megalin with highly conserved sequences of AGT:
(1) big size of megalin (about 600 kD)[180, 181] causing the difficulty of purification, and
(2) low AGT protein production due to mutations. Moreover, since mutation on the β-sheet
did not change plasma AGT concentration and blood pressure as well as atherosclerosis,
we only investigated whether the loop region is essential for AGT binding to megalin in
SPR analysis. The data showed that W292 in the loop region is involved in the interaction
with megalin. Megalin has four ligand-binding regions [180]. Therefore, future studies
will aim to study potential interactions of AGT with which ligand-binding domains to
investigate and explore the potential roles of local RAS in development of atherosclerosis.
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CHAPTER 5. GENERAL DISCUSSION – LIMITATIONS, SOLUTIONS AND CONTRIBUTIONS OF
STUDIES REGARDING SPECIFIC DOMAINS OF AGT IN ANGII-MEDIATED FUNCTIONS
This chapter is an overall discussion based on chapter 3 and 4. This chapter
discusses the limitations of these studies, the ways to solve problems, future directions, and
importance and contributions of these studies in cardiovascular diseases.

5.1

Amino acids adjacent to renin cleavage site (Chapter 3)
Our results showed that two amino acids at position 11 and 12 adjacent to renin

cleavage site in mouse AGT do not affect renin cleavage of AGT and consequently AngIImediated functions in hepAGT-/- mice. This results support the in vitro finding of Hatae at
el. [182], but are contrary to the data of Burton et al who demonstrated that the amino acids
are critical for renin cleavage of AGT by using synthetic tetradecapeptides and human or
canine renin. These results implicate that amino acid residues next to renin cleavage site
in different species might have different effects on catalytic activity of renin from different
species. In addition to amino acids, tertiary protein structure of AGT and specificities of
renin from different species might also contribute to the efficiency of renin cleavage of
AGT.
N-terminal amino acids around renin cleavage sites also regulate the catalytic
activity of renin. 12' isoleucine replaced by tyrosine residue in human tetradecapeptide
significantly decreased kcat of renin [104]. Six residues surrounding the renin cleavage site
of human AGT are important for human renin action [106]. In a preeclamptic patient, there
was a mutation with the replacement of leucine by phenylalanine at position 10 of AGT
(L10F), which altered the reaction of AGT with renin [183]. These studies show the other
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potential amino acids regulating renin activity. Our previous studies reported that there are
highly conserved regions in AGT, including hydrophobic core, AngI, renin interacting face,
β-sheet and loop region [59]. Conserved sequence of renin interacting face may determine
the efficiency of renin cleavage of AGT. Future studies will aim to manipulate conserved
residues in this renin-interacting region to determine whether certain amino acid sequences
in this region affect the tertiary protein structure or interaction with renin.
In addition, plasma L11V;Y12I mouse AGT repopulation showed difference in
hepAGT-/- male (Fig. 3.5A) and female mice (Fig. 3.7A). Much lower plasma AGT
concentrations was expressed in female hepAGT-/- mice infected AAV encoding mouse
AGT(L11V;Y12I) than in their hepAGT+/+ littermates. This sex difference has also been
reported in mice injected with AAV encoding PCSK9 [172, 173], although the mechanism
of AAV-mediated protein expression contributing to sex difference is unclear. For mouse
AGT measurement, we have been using the same ELISA kit for more than 10 years (the
best kit among 4 commercially available kits we tested) and documented the batch number
of the ELISA kit in each experiment as a lab routine. Despite the same kit which has been
used, different batch number and measurements conducted by different persons might get
the slightly different absolute values of AGT concentrations (Table 5-1).
Table 5-1 Plasma AGT concentrations in wild type mice measured using different
batches of the mouse AGT ELISA kit (Code # 27413; IBL America).
Batch #
Date performed
Sex
Plasma AGT (ng/ml)
Male
2868 ± 668
1K-226
11/07/2013
Female
3063 ± 299
1I-412
02/03/2015
Male
3592 ± 253
1J-427
10/05/2017
Male
3620 ± 128
1F-713
03/08/2018
Female
1798 ± 30
1C-3
09/04/2018
Male
1760 ± 56
1B-820
05/30/2020
Male
1554 ± 47
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Systolic blood pressures in hepAGT+/+ mice were about 140-160 mmHg in Human
AGT AAV study and L11V;Y12I AGT AAV study (Chapter 3) and conserved regions
AGT studies (Chapter 4) by using a tail-cuff system, CODA high throughput system (Kent
Scientific). Hypertension is defined as a systolic blood pressure (SBP) ≥130 mmHg and a
diastolic blood pressure (DBP) ≥80 mmHg in adults [184]. Compared to human, SBP in
hepAGT+/+ mouse was relatively high. The accuracy of this tail-cuff system is affected by
many factors, including environment temperature, stress on mice and tail blood volume
status. (1) Multiple training sessions, (2) taping the distal part of the tail on the platform,
(3) cover the animal holder to reduce light and noise, and (4) check the temperature of
platform are helpful to minimize agitation of mice and reduce issues in SBP measurement
[185, 186]. In contrast, a tail-cuff blood pressure measurement has several advantages. For
example, measurements in conscious animals are close to physiological conditions. A tailcuff system is a simple and rapid way to test blood pressure within multiple animals,
without anesthesia or invasive surgery. Moreover, in our previous publications, hepAGT+/+
mice also had consistent systolic blood pressures [56, 59], suggesting that comparability
of data in our blood pressure measurement.

5.2

Highly conserved regions of AGT (Chapter 4)
Our results showed that highly conserved regions, the β-sheet and loop region of

AGT synergistically regulate AGT synthesis and consequently AngII-mediated functions,
which reveals a novel biological function of these highly conserved regions. Moreover,
the loop region might be one of critical region determining the interaction with megalin.
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AGT with (1) a single nucleotide mutation on the loop region, (2) triple nucleotide
mutations on the loop region, (3) triple nucleotide mutations on the β-sheet, or (4) loop
deletion mutation all did not affect blood pressure and atherosclerosis in hepAGT-/- mice
fed a Western diet for 12 weeks. The RAS are regulated under different stress conditions,
such as high salt intake and low salt intake, which associates with hypertension [187-190].
Thus, whether expression of AGT mutants exerts different effects on AngII-mediated
functions in mice fed a high salt diet or low salt diet is another future direction to study the
functions of conserved regions of AGT in AGT metabolism and AngII-mediated functions
in mice under stress conditions.
Plasma AGT concentration was moderately increased in hepAGT-/- mice infected
with AAV encoding AGT with loop deletion, and blood pressure and atherosclerosis in
these mice were significantly increased to a comparable level to hpeAGT+/+ mice infected
with null AAV. However, hepAGT-/- mice infected with AAV encoding AGT with
mutation on the β-sheet and loop region failed to repopulate AGT mutant, increase blood
pressure and atherosclerosis which were all comparable to hepAGT-/- mice infected with
null AAV. The question here is what the exact concentration of AGT can produce AngII
which concentration is enough to regulate and affect blood pressure and atherosclerosis. It
is difficult to define biological functions which are affected by a specific dose of AGT. To
address this question, hepAGT+/+ mice could be injected with different doses of GalNAcconjugated AGT antisense oligonucleotides (ASO) to specifically inhibit AGT expression
in hepatocytes. Blood pressure and atherosclerosis could be tested in hepAGT+/+ mice
expressing with different concentrations of AGT.
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In this study, we only tested the interaction of megalin and AGT with a single
nucleotide mutation (W292A). There are some difficulties limiting the assessments of the
binding affinities of other mutated AGT with megalin. Firstly, megalin is about 600-kD
membrane-bound protein [180, 181], which big size causing the difficulty of purification.
Secondly, mutations on the β-sheet and loop region at the same time cause the low
recombinant AGT protein production.
In the future studies, to solve the problem of purification of megalin, four ligandbinding domains of megalin can be generated separately or generated with different
combinations to investigate more detailed interactions between AGT and megalin in vitro.
In addition to using purified megalin protein, megalin-expressing cells [191, 192] can be
used to study the interaction of AGT with megalin in cells. Retinoic acids and dibutyrl
cAMP-treated F9 cells (testicular teratoma stem cell line; ATCC) express megalin (Fig.
5.1). I used recombinant AGT proteins with flag-tag labeling (generated by GenScript) to
do AGT uptake experiment in F9 cells to study the interaction of AGT with megalin.
However, I failed to get consistent results from cell immunofluorescent staining and
western blotting analysis (Fig. 5.2). There were some issues in this experiment: (1)
antibody targeting AGT was failed to detect AGT in cells. Also, antibody targeting flag
tag did not specifically bind to AGT in western blotting analysis, suggesting that AGT
detected in cell immunofluorescent staining by anti-flag antibody might be a non-specific
result; (2) how long is enough for AGT uptake into cells is still unclear. Thus, to figure
out the availability of specific antibodies targeting recombinant AGT protein and the
optimal AGT incubation time and condition is the first thing to do in the future studies.
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Figure 5.1 Immunofluorescence confocal microscopy of F9 cells.
F9 cells express megalin after retinoic acids and dibutyrl cAMP incubation for 4 days.
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Figure 5.2 Recombinant AGT protein uptake experiments in F9 cells.
F9 cells incubated with retinoic acids and dibutyrl cAMP for 4 days to induce megalin
expression, and then incubated with 30 nM recombinant AGT for 30 min or 1 h. (A) Fixed
cells were stained with DAPI, anti-megalin antibody, anti-flag antibody or anti-AGT
antibody. (B) Cell lysates were used for western blotting analysis. Rabbit anti-flag: IRDye
800CW (green color). Mouse anti-mouse b-actin: IRDye 680RD (red color).
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Since megalin is predominantly expressed in renal proximal tubules, mouse renal
proximal tubule cell (TKPTS; ATCC) was used to test the expression of megalin. However,
megalin was not detected in TKPTS (Fig. 5.3). Although megalin-expressing cells can
potentially be used for experiments of AGT and megalin interaction, the further megalin
expression confirmation in other cells (e.g. HK-2 cell) and cell culture condition will need
to be verified.

Figure 5.3 TKPTS cells did not express megalin.
TKPTS cell lysate was used for western blotting analysis. Rabbit anti-human megalin:
IRDye 680RD (red color). Mouse anti-mouse b-actin: IRDye 800CW (green color).

In addition, to solve the problem of recombinant AGT protein production, our
collaborator, Dr. Vander Kooi in Molecular and Cellular Biochemistry at the University
of Kentucky will try to use different cell expression systems to generate recombinant AGT
with different mutations for the future studies.
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5.3

Perspectives
AGT is the only precursor of all angiotensin peptides, so how AGT is regulated is

critical for many pathophysiological functions which mediated by angiotensin peptides.
Moreover, targeting AGT acts as a potential therapeutic method of many angiotensinmediated diseases. For example, maternal liver-derived AGT inhibition by siRNA
improved pre-eclampsia phenotypes, such as blood pressure and the fetus growth
restriction [70]. In addition, liver-specific AGT inhibition by N-acetylgalactosamine
(GalNAc)-conjugated antisense oligonucleotides (ASO) targeting AGT reduced blood
pressure in spontaneously hypertensive rats fed an 8 % NaCl diet which is a hypertension
model resistant to the RAS inhibitors and protected renal functions in rats salt-deprived
which is a model activating renin production and activity [62], showing a promising roles
of targeting AGT in treatment of hypertension and kidney injury. Therefore, to understand
how AGT function and metabolism are regulated benefits the development of therapy by
targeting AGT. Our previous paper demonstrates that AGT and megalin interactions
regulate renal RAS homeostasis and development of atherosclerosis [57], indicating the
pivotal roles of local renal RAS in AngII-mediated diseases. In our future study,
understanding the potential interactions between AGT and megalin would provide
evidence how AGT is regulated locally and how local RAS affects AngII-mediated
diseases, which might facilitate the development of therapeutic treatment targeting tissuespecific AGT in AngII-associated diseases.
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